Anti-Mouse/Human PD-L1 / VEGF-A Bispecific Antibodies [16337] - $0.00 : Syd Labs - Speed up Your Discovery

Description

Background

What is Atezolizumab biosimilar research grade? Atezolizumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1, with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab is an Fc-engineered, humanized, monoclonal antibody (IgG1κ isotype). Atezolizumab biosimilar uses the same protein sequences as the therapeutic antibody atezolizumab. Atezolizumab lacks the N-glycosylation site in its Fc region by changing an aspartic acid into alanine at amino acid position 298 (amino acid position 297 according to EU nomenclature, N297A) in the heavy chain leading to minimized binding to FcγRs.

PD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Atezolizumab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body’s adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.

It is under investigation how the recombinant anti-mouse/human PD-L1 / VEGF-A bispecific antibodies (Ate / G6-23) behave different from the individual monoclonal antibodies and their combination.

Our recombinant anti-mouse/human PD-L1 / VEGF-A bispecific antibodies have a part (variable regions) or complete amino acid sequences of the anti-mouse/human PD-L1 antibody Atezolizumab and the mouse anti-mouse/human VEGF antibody (hybridoma clone name or number: G6-23).

PA008039.m2cLA: In Vivo Grade Recombinant Anti-mouse/human PD-L1 / VEGF-A Bispecific Antibody, Mouse IgG2c LALAPG Kappa (Clone Ate / G6-23)

The in vivo grade recombinant anti-mouse/human PD-L1 / VEGF-A bispecific antibody (mouse IgG2c LALAPG Kappa) was produced in mammalian cells.
Clone: Ate, the same variable region sequences as the the anti-mouse/human PD-L1 antibody Atezolizumab. G6-23, the same variable region sequences as the mouse anti-mouse/human VEGF monoclonal antibody (clone number: G6-23).
Isotype: mouse IgG2c, kappa.
Applications: immunohistochemistry (IHC), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

Shipping: The in vivo grade recombinant anti-mouse/human PD-L1 / VEGF-A bispecific antibodies are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
1 month from date of receipt, 2 to 8°C as supplied.
12 months from date of receipt, -20°C to -70°C as supplied.

Recombinant anti-HEL / HEL Bispecific Isotype Control Antibodies:
In vivo Grade Recombinant anti-HEL / HEL Mouse IgG1 Kappa Bispecific Isotype Control Antibody
In vivo Grade Recombinant anti-HEL / HEL Mouse IgG2a Kappa Bispecific Isotype Control Antibody
In vivo Grade Recombinant anti-HEL / HEL Mouse IgG2c Kappa Bispecific Isotype Control Antibody

Syd Labs provides the following anti-mouse PD1 (PD-L1) and VEGFA monoclonal antibodies:
In vivo grade recombinant anti-mouse PD-1 monoclonal antibodies (Clone RMP1-14.1)
In vivo grade recombinant anti-mouse PD 1 monoclonal antibodies (Clone 29F.1A12.1)
In vivo grade recombinant anti-mouse PD-L1 monoclonal antibodies (Clone 10F.9G2.1)
In vivo grade recombinant anti-mouse VEGFA monoclonal antibodies (Clone B20-4.1.1.1))
In vivo grade recombinant anti-mouse VEGF-A monoclonal antibodies (Clone G6-31)
In vivo grade recombinant anti-mouse VEGF monoclonal antibodies (Clone G6-23)

Syd Labs provides the following anti-mouse PD-1 / VEGFA bispecific antibodies:
In vivo grade recombinant anti-mouse PD-1 / VEGF-A bispecific antibodies (Clone RMP1-14.1 / B20-4.1.1.1)
In vivo grade recombinant anti-mouse PD1 / VEGFA bispecific antibodies (Clone 29F.1A12.1 / B20-4.1.1.1)
In vivo grade recombinant anti-mouse PD-1 / VEGF bispecific antibodies (Clone RMP1-14.1 / G6-23)
In vivo grade recombinant anti-mouse PD1 / VEGF bispecific antibodies (Clone 29F.1A12.1 / G6-23)
In vivo grade recombinant anti-mouse PD 1 / VEGF bispecific antibodies (Clone RMP1-14.1 / G6-31)
In vivo grade recombinant anti-mouse PD-1 / VEGF A bispecific antibodies (Clone 29F.1A12.1 / G6-31)

Syd Labs provides the following anti-mouse PD-L1 / VEGFA bispecific antibodies:
In vivo grade recombinant anti-mouse PD-L1 / VEGF-A bispecific antibodies (Clone 10F.9G2.1 / B20-4.1.1.1)
In vivo grade recombinant anti-mouse PD-L1 / VEGF bispecific antibodies (Clone 10F.9G2.1 / G6-23)
In vivo grade recombinant anti-mouse PDL1 / VEGF bispecific antibodies (Clone 10F.9G2.1 / G6-31)

Syd Labs provides the following anti-mouse PD-1 / CTLA-4 bispecific antibodies:
In vivo grade recombinant anti-mouse PD-1 / CTLA-4 bispecific antibodies (Clone RMP1-14.1 / 9D9)
In vivo grade recombinant anti-mouse PD-1 / CTLA4 bispecific antibodies (Clone 29F.1A12.1 / 9D9)

Syd Labs provides the following anti-mouse PD-1 / TIGIT bispecific antibodies:
In vivo grade recombinant anti-mouse PD-1 / TIGIT bispecific antibodies (Clone 29F.1A12.1 / 1F4)
In vivo grade recombinant anti-mouse TIGIT / PD-1 bispecific antibodies (Clone 1F4 / 29F.1A12.1)